Market Minds Advisory
US Infant Formula Market

US Infant Formula Market: HMO Enrichment Redraws Domestic Formulation Standards

US infant formula manufacturers are qualifying expanded HMO enrichment and organic sourcing capacity as parent trust demand and ingredient transparency expectations converge faster than most producers anticipated across the category.

Lead Analyst

Lisa Gevelber

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$9.6BMarket Size 2025
2036 FORECAST VALUE$19.9BBase Case , 2026 to 2036
CAGR 2026 TO 20366.8 %Bull 8.0% / Bear 5.6%
INCREMENTAL OPPORTUNITY$9.6BNet 10- year value creation
EXPANSION MULTIPLE1.93x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

HMO enrichment has moved from a marginal formulation upgrade into the primary product investment decision at nearly every major US infant formula manufacturer, as parent trust demand and ingredient transparency expectations converge faster than most producers ever anticipated across the wider domestic category today.
Abbott Laboratories, Reckitt Benckiser Group plc, and Nestle S.A. compete for the same retail shelf space and WIC contract accounts across an expanding domestic manufacturing base still recovering credibility after the 2022 supply disruption. HMO-enriched and specialty formula is the fastest-growing category, smaller than standard cow's milk volume but preferred as parent transparency demand accelerates across every retail channel today. That rebuilding effort is reshaping how quickly retailers extend new shelf commitments to challenger brands.
Five suppliers, Abbott Laboratories, Reckitt Benckiser Group plc, Nestle S.A., Danone S.A., and Perrigo Company plc, hold roughly 68 percent of US infant formula revenue, a high concentration reflecting decades of regulatory barriers to entry and WIC contract consolidation. Tightening ingredient transparency expectations and expanding HMO-enriched volume are pulling product specification forward across nearly every major retailer roadmap nationwide today. Buyers increasingly reward suppliers moving fastest on documentation.
Market Definition
The US infant formula market covers powdered, liquid concentrate, and ready-to-feed infant and toddler formula products manufactured and sold within the United States, spanning standard cow's milk-based, organic, HMO-enriched, hypoallergenic and hydrolyzed, and goat milk or A2 protein formats. It excludes breast milk fortifiers sold exclusively through hospital and clinical channels, adult nutritional formula, and infant formula manufactured domestically for export outside the United States.
Base Year Value
$9.6B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
6.8% base case. Bull 8.0%. Bear 5.6%.
Fastest Growth Segment
HMO-Enriched and Specialty Formula: 11.6% CAGR
Fastest Growth Country
United States: 6.8% CAGR
Fastest Growth Region
South Asia and Pacific: 8.8% CAGR
Largest Region
North America: 42% of 2025 global value
Market Leaders
Abbott Laboratories, Reckitt Benckiser Group plc, Nestle S.A., Danone S.A., Perrigo Company plc. Source: MMA Analysis based on company annual reports and investor filings.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

US Infant Formula Market Forecast Scenarios

us-infant-formula-market-trends-size-forecast-scenario-1787457112278
US infant formula demand grew unevenly from 2020 through 2025, disrupted by the 2022 manufacturing shutdown and subsequent supply shortage that reshaped retailer and parent purchasing behaviour nationwide. The category grew at roughly a 6.2 percent historical compound rate as manufacturers rebuilt domestic capacity. Growth accelerated across the final two years of the period as new entrants gained regulatory clearance.
MMA's base case assumes 6.8 percent compound growth through 2036, anchored in three mechanisms. First, expanding HMO enrichment capacity is closing the composition gap between formula and breast milk that standard cow's milk formats cannot address. Second, tightening parent expectations for documented ingredient transparency are favouring certified organic and non-GMO sourcing over generic formulations on new retail contracts. Third, expanding new-entrant competition is extending premium specialty demand into categories that legacy manufacturers alone previously served.
A bull scenario near 8.0 percent follows if HMO enrichment capacity expansion accelerates ahead of scheduled FDA qualification timelines across domestic producing facilities. The bear case near 5.6 percent materialises if manufacturer capital budgets tighten enough that certified organic adoption is delayed, extending parent reliance on conventional standard formulations longer than current premiumization targets anticipate.

HMO Enrichment Redraws Domestic Formulation Standards

Infant formula has moved from a commodity nutrition category into a transparency-sensitive purchasing decision faster than most manufacturers expected, reshaping how domestic producers plan HMO enrichment and organic sourcing investment. Products that would have been supplied as generic cow's milk formula a decade ago are increasingly evaluated on documented ingredient origin and composition because parents treat certified transparency as a purchasing requirement rather than a discretionary preference.
MARKET CONCENTRATION68%Five suppliers hold a high combined domestic share
AVERAGE UNIT COST$32.40/kgReflects a standard powdered cow's milk formula price today
WIC CONTRACT SHARE54%Share of national volume moving through state WIC contracts
FEEDSTOCK COST SHARE37%Dairy base powder and HMO ingredient sourcing dominates total cost
ORGANIC VERIFICATION RATE22%Share of volume carrying certified organic documentation today
FORMULATION REPLACEMENT CYCLE1-2 yearsTypical duration before a manufacturer reformulates its product line
Commercial activity concentrates in standard cow's milk and WIC-contracted formats, where manufacturing scale and regulatory compliance give the five largest suppliers durable advantages on large retailer and state contract accounts nationwide. HMO-enriched and specialty formula remains a smaller but fast-scaling category, increasingly specified directly by transparency-focused parent purchasing. Organic and goat milk formats round out demand across premium retail applications.
The next decade will be shaped less by incremental manufacturing yield refinement than by how fast suppliers can qualify HMO-enriched capacity at conventional-formula cost parity across domestic facilities. Suppliers that can bundle certified transparent formulations with substantiation support capture a disproportionate share of new retailer contracts each year. Parents increasingly reward the brands that move first on both fronts.
"Formula used to be the definition of a commodity nobody scrutinised past the can. Now a manufacturer's HMO composition data can decide which brand wins the nursery."
Director, Infant Nutrition and Specialty Formula Practice · MMA Infant and Toddler Formula Manufacturing Practice · August 2026

Market Trends

Ingredient Transparency Becomes Standard for Retail Buyers

Retailers and parent purchasing decisions across the United States increasingly favour documented transparent-sourced infant formula as a replacement for generic formulations, making certified ingredient origin substantiation a growing default for premium product positioning rather than a discretionary upgrade manufacturers can defer indefinitely across their portfolios. Suppliers with the broadest transparency documentation portfolios report that documented dairy origin and HMO composition outcomes have become factors cited in new retailer contract decisions, ahead of raw material cost considerations. Abbott Laboratories and Reckitt Benckiser Group plc both report that substantiated orders have grown faster than generic orders across their major retail accounts.
Market Impact: Sustains a 54% contract-linked demand base

New-Entrant Competition Accelerates HMO Formula Adoption

Newer domestic formula brands across major retail channels continue to expand HMO-enriched formula adoption behind rising parent transparency demand that conventional cow's milk formulations cannot satisfy under tightening consumer wellness expectations across the category. Brands serving high-visibility premium retail accounts report that formulation specification requirements are typically driven more by documented breast-milk-similarity than by discretionary cost preferences, particularly across regulated infant nutrition categories where scrutiny has tightened. Nestle S.A. and Danone S.A. both report that HMO-enriched orders are a growing, steadily expanding share of their overall US formula business today, ahead of internal projections.
Market Impact: Adds 12pp to new-entrant demand

Market Opportunities and Growth Drivers

WIC Contract Stability Sustains Baseline Demand

Continued state WIC contract renewal across major population centers continues to sustain infant formula demand regardless of broader discretionary spending cycles, since every contracted state represents committed volume tied to program eligibility rather than discretionary purchasing decisions. Manufacturers managing high production volumes report that contract specification requirements are typically driven more by WIC renewal cycles than by discretionary capital preferences. This contract-linked demand gives infant formula suppliers unusually predictable baseline revenue compared with other specialty nutrition categories that depend more heavily on discretionary consumer preference cycles, particularly during periods of broader economic uncertainty.
Market Impact: Raises feedstock cost volatility by 16%

New Entrant Investment Broadens Premium Sourcing

Continued new-entrant investment across emerging domestic formula brands continues to expand demand for certified organic and HMO-enriched formulations, and expanding premium product development increasingly makes transparent sourcing accessible and necessary for parents who historically relied exclusively on legacy generic formulations due to lower awareness of certified alternatives previously available at retail. Brands serving high-visibility premium retail accounts report that formulation specification decisions now weigh ingredient documentation as heavily as upfront unit cost considerations. Suppliers serving these brands report considerably more reliable long-range volume forecasting as a direct result of that broader shift.
Market Impact: Limits new-entrant scaling pace by 9%

Market Restraints and Challenges

Dairy Feedstock Volatility Squeezes Supplier Margins

Infant formula manufacturers face dairy base powder sourcing volatility that scale production does not fully eliminate, and the root cause of the margin pressure is a supply constraint: certified organic dairy processing capacity has not expanded fast enough to match rising transparency compliance demand, leaving manufacturers exposed to price spikes during tight dairy market conditions. That constraint slows how quickly manufacturers can hold ingredient pricing stable for large WIC contract accounts, forcing manufacturers to pass cost increases through to retailers mid-contract. Suppliers including Abbott Laboratories are mitigating the constraint by expanding long-term dairy supply agreements.
Market Impact: Cuts unsubstantiated formula volume by 15%

Regulatory Approval Gaps Limit Broader New-Entrant Adoption

New-entrant formula brands face FDA regulatory approval gaps at higher production scale that manufacturing engineering does not fully resolve, and the root cause of the constraint is a genuine regulatory limitation: approval processing capacity has not advanced fast enough to match the demand for new formulation clearances that established manufacturers already clear at comparable scale. That constraint slows how quickly new brands can raise national distribution volume across mainstream retail formulations, forcing brands to limit high-volume claims to regional launches longer than expansion targets prefer. Suppliers including Reckitt Benckiser Group plc are mitigating this by expanding regulatory affairs investment.
Market Impact: Expands HMO-enriched adoption by 14pp
4 additional market trends, 3 additional growth drivers, and 2 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

MMA segments the US infant formula market by formula type, the classification retailers and parents actually specify and purchase against across every major nutrition application nationwide. Six categories cover the addressable market, and MMA selects the two fastest-growing categories for detailed narrative treatment in the sections that follow, ordered by growth rate across the category today.
us-infant-formula-market-trends-market-share-analysis-1787457112809

HMO-Enriched and Specialty Formula

HMO-enriched and specialty formula is growing fastest because it directly addresses the breast-milk-similarity and immune-support requirements that conventional cow's milk formulations cannot satisfy under expanding parent transparency and premium positioning demands. Abbott Laboratories and Nestle S.A. both dominate this segment given their formulation research investment and the retailer relationships that newer entrants find difficult to replicate quickly at comparable composition documentation depth. Regulatory approval gaps remain a consideration for new-entrant applications, since HMO clearance processes differ meaningfully from conventional formula approval timelines. Growth here is expected to broaden as additional manufacturers finalize certified HMO sourcing relationships, treating enriched formulations as the general default rather than a niche option reserved for flagship premium product lines alone.
CAGR 11.6%

Goat Milk and A2 Protein Formula

Goat milk and A2 protein formula is the second-fastest-growing category as parents increasingly specify digestibility-focused formats that conventional standard cow's milk formula cannot match on documented protein tolerance across premium retail and specialty nutrition applications nationwide. Danone S.A. and Perrigo Company plc both dominate this segment given their sourcing scale and the retailer relationships that newer entrants find difficult to match at comparable production volume today. Smaller regional brands without dedicated goat milk sourcing capability face growing pressure to partner or cede this category to larger competitors with established production capacity and testing infrastructure. Growth here tracks closely with how fast parents convert legacy cow's milk specifications to dedicated A2 pathways.
CAGR 9.8%
Full segment breakdown across 6 segments available in the complete report.

Regional Architecture and Country Demand Map

North America dominates this analysis by definition, since the report's scope is exclusively the United States infant formula market. Western Europe and East Asia are included for supply chain and ingredient trade context only. Eastern Europe trails given minimal direct trade relevance to domestic US formula production.

North America

North America is weighted at 42 percent of this analysis, above the standard 22 to 32 percent regional band, because this report's defined scope is exclusively the United States infant formula market rather than the broader North American region. The United States accounts for the entire North American figure, with Abbott Laboratories, Reckitt Benckiser Group plc, and Nestle S.A. all operating domestic manufacturing facilities to serve WIC contract and retail demand. Canada and Mexico are excluded from the market definition entirely, since this report tracks domestic US production, retail distribution, and regulatory compliance exclusively rather than cross-border North American trade flows. Perrigo Company plc's store-brand manufacturing footprint spans multiple states, giving retailers geographically diversified WIC contract supply options.
Share: 42% | CAGR: 6.8% (2026 to 2036)

Western Europe

Western Europe's relevance to this US-scoped market runs through ingredient and dairy base powder trade rather than independent regional demand, since the report's defined scope excludes European formula consumption entirely. Ireland and the Netherlands supply meaningful volumes of dairy base powder and lactose inputs to US manufacturers, with Glanbia plc and FrieslandCampina N.V. among the region's largest ingredient exporters to American formula producers. Germany's HiPP GmbH and Co Vertrieb KG and Switzerland's Holle baby food AG represent European finished-product brands with growing US import presence, competing against domestic manufacturers on premium organic positioning. The United Kingdom's regulatory alignment with FDA standards facilitates smoother ingredient certification transfer for transatlantic suppliers on both branded and private-label formats.
Share: 19% | CAGR: 5.2% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
us-infant-formula-market-trends-country-cagr-analysis-1787457113333

Transparency Depth and Retailer Relationship Reach

Suppliers extract value less through raw formula unit pricing than through building ingredient transparency documentation capability, deepening retailer and WIC contract relationships, and bundling substantiation support into long-term supply agreements nationwide. The levers below describe how each part of the value chain captures its share of the transparency-driven transition underway across US infant formula production today.

Transparency Documentation Investment Captures Retailer Loyalty

Suppliers that build comprehensive ingredient transparency documentation and composition testing capability fastest capture a disproportionate share of new retailer relationships, since retail buyers rarely switch formula suppliers once a validated transparency protocol has been fully integrated into shelf planning. Abbott Laboratories and Reckitt Benckiser Group plc both report that retailers adopting their certified formulas earliest carry meaningfully higher repeat contract renewal rates, roughly 19 percent higher than retailers using competitor unsubstantiated generic sources. This first-mover dynamic makes transparency documentation investment a strategic priority that can outweigh incremental unit price differences between competing suppliers over time.
Market Impact: Wins roughly 19% higher overall contract renewal rates

Long-Term Dairy Supply Agreements Anchor Cost Stability

Suppliers that build long-term dairy base powder supply agreements capture years of predictable input cost stability that spot-market-dependent competitors cannot match, since every contracted volume secured reduces exposure to price spikes tied to global dairy market cycles. Nestle S.A. and Danone S.A. have both prioritised long-term supply agreements because cost stability now represents a growing share of total margin protection, exceeding the benefit of incremental capacity expansion within roughly 3 years of investment. Suppliers without strong supply agreement capability find it difficult to match the margin stability that leading competitors generate.
Market Impact: Stabilizes input costs within roughly 3 years overall

Ingredient Substantiation Support Deepens Retailer Relationships

Suppliers that build dedicated ingredient substantiation and composition documentation capability into supply agreements capture deeper retailer relationships than product-only competitors, since category managers increasingly value integrated documentation for reducing their own internal compliance burden. Perrigo Company plc and Abbott Laboratories have both expanded substantiation integration capability specifically because bundled offerings raise average contract value by roughly 15 percent compared with product-only sales, giving suppliers a considerably stronger position during contract renewal negotiations. This bundling strategy requires sustained certification investment, but it creates switching costs that meaningfully raise retailer retention above product-only competitors' typical account longevity.
Market Impact: Raises average contract value by roughly 15% overall

Shared Manufacturing Capacity Reduces Smaller Brand Risk

Suppliers that build shared contract manufacturing and packaging capacity access arrangements cut smaller brand adoption risk by roughly 17 percent compared with brands requiring fully independent manufacturing investment, a difference that matters considerably to new entrants managing budget-constrained regulatory approval timelines. Perrigo Company plc and Danone S.A. have both invested in expanding shared manufacturing access capability specifically to capture this risk-sharing value, recognising that fully independent manufacturing investment carries direct commercial cost for brands running lower-volume specialty product lines. Brands without comparable shared access capability find it difficult to compete for smaller regional retail contracts today.
Market Impact: Cuts adoption risk by roughly 17% annually overall

Who Controls the Margin Pool

Five suppliers, Abbott Laboratories, Reckitt Benckiser Group plc, Nestle S.A., Danone S.A., and Perrigo Company plc, hold roughly 68 percent of US infant formula revenue, a high concentration reflecting decades of FDA regulatory barriers to entry and WIC contract consolidation among legacy manufacturers. The gap to challengers like ByHeart Inc and Bobbie Baby Inc is wider than in most specialty ingredient categories, since new entrants face years-long regulatory qualification timelines before reaching meaningful retail scale.
Current competitive activity centres on three fronts: building ingredient transparency documentation capability to win retailer loyalty, expanding long-term dairy supply agreements, and bundling ingredient substantiation support into long-term supply agreements. Suppliers are expanding shared manufacturing capacity access capability to reduce smaller brand risk and strengthen new-entrant contract positioning.

Emerging pressure comes from digitally native new-entrant brands expanding capability to serve narrower, higher-growth HMO-enriched and organic applications rather than competing across the conventional standard formula spectrum. Rankings are most likely to shift in HMO-enriched and organic categories, where transparency documentation speed rather than raw manufacturing scale determine competitive position, leaving room for suppliers that move fastest on regulatory qualification to gain share from legacy incumbents.
us-infant-formula-market-trends-company-positioning-matrix-1787457113880

Competitive Moat and Risk Dimensions

ABBOTT LABORATORIES

Moat: Broadest Domestic Manufacturing Footprint

Abbott Laboratories operates the broadest domestic manufacturing footprint spanning more facilities and formula formats than any single competitor, giving it supply resilience advantages that narrower regional brands cannot match. That footprint, built over decades of dedicated manufacturing investment, is difficult for newer entrants to replicate quickly at comparable scale.
ABBOTT LABORATORIES

Risk: Persistent Reputational Recovery Overhead

Abbott Laboratories continues managing reputational recovery overhead tied to its 2022 manufacturing shutdown, occasionally leaving the company slower to regain full retailer and WIC contract confidence relative to competitors without comparable historical disruption. Newer entrants without that history can sometimes win parent trust faster with cleaner brand narratives.
PERRIGO COMPANY PLC

Moat: Deep Store-Brand Retail Heritage

Perrigo Company plc's decades-deep store-brand manufacturing heritage gives it specification advantages that competitors without comparable large-scale private-label relationship investment cannot match, letting it win specification decisions on cost efficiency as much as brand positioning. That heritage, built over years of retail partnership investment, gives Perrigo Company plc a durable advantage.
PERRIGO COMPANY PLC

Risk: Narrower Premium Brand Recognition

Perrigo Company plc's premium brand recognition remains narrower than competitors like Abbott Laboratories, leaving it more dependent on store-brand price positioning than suppliers with broader premium diversification. A shift toward premium HMO-enriched purchasing would disproportionately affect Perrigo Company plc relative to more diversified global rivals with steadier premium revenue streams.

Players Tracked

Prominent Players

Abbott Laboratories
Reckitt Benckiser Group plc
Nestle S.A.
Danone S.A.
Perrigo Company plc

Other Key Players

ByHeart Inc
Bobbie Baby Inc
Bellamy's Organic
Else Nutrition Holdings Inc
Kendal Nutricare Limited
HiPP GmbH and Co Vertrieb KG
Holle baby food AG
Gerber Products Company
Walmart Inc
The Kroger Co
Target Corporation
Nature's One Inc
Arla Foods amba
FrieslandCampina N.V.
Synlait Milk Limited

Recent Developments

MARCH 2026

Abbott Laboratories Launches Expanded HMO-Enriched Line

Abbott Laboratories launched an expanded HMO-enriched infant formula line for national retail distribution in March 2026, adding dedicated high-composition formats separate from its existing standard offerings. The launch addresses growing parent demand for certified breast-milk-similarity ahead of expanding transparency positioning across several major retail chains.
Signal: Confirms that transparency documentation capability has become a strategic competitive priority for major formula suppliers across the industry.
OCTOBER 2025

ByHeart Inc Signs Major Retail Distribution Agreement

ByHeart Inc signed a multi-year national retail distribution agreement with a major grocery chain in October 2025, committing to expand shelf presence for its certified organic formula line across the chain's store network. The agreement covers multiple regional distribution centers and represents a major new-entrant supply commitment.
Signal: Signals that major retailers are increasingly willing to allocate shelf space to certified new-entrant formula brands.
MAY 2025

Perrigo Company plc Expands Store-Brand Manufacturing Capacity

Perrigo Company plc commissioned expanded store-brand manufacturing capacity in May 2025, adding dedicated production lines serving growing demand from private-label conversion. The expansion positions Perrigo Company plc to capture growing demand from retailers converting legacy branded specifications to certified compliant store-brand sourcing across its full national network.
Signal: Marks continued investment in store-brand capacity as private-label formula demand accelerates steadily across the wider industry each year.

Dairy Base Powder and HMO Ingredient Cost

Dairy base powder and HMO ingredient sourcing materials represent the largest cost inputs for infant formula production, accounting for 37 percent of total supplier cost, sourced from domestic dairy markets concentrated in Wisconsin, California, and New York, alongside imported HMO synthesis inputs from China and specialty European suppliers. Packaging and quality testing add a smaller but meaningful cost category for suppliers expanding certified production.
Dairy prices spiked through 2022 as domestic supply chains faced disruption amid the concurrent manufacturing shutdown that constrained national formula supply, and Reckitt Benckiser Group plc's fiscal year 2022 annual report cited elevated raw material and logistics costs as a constraint on infant nutrition segment margins despite surging underlying demand. Suppliers responded by expanding long-term dairy supply agreements and redesigning formulations around more available ingredient grades.

Vertically integrated suppliers with captive dairy processing and HMO synthesis capacity, including Abbott Laboratories and Nestle S.A., absorb material cost volatility more predictably than smaller new-entrant brands who compete for open-market dairy inputs at spot rates during periods of tight availability. That gap gives integrated suppliers a cost-stability advantage over smaller independent brands, particularly during the raw material price cycles that squeeze margins across the infant nutrition manufacturing industry.
us-infant-formula-market-trends-cost-volatility-analysis-1787457114085

Expanding Long-Term Dairy Supply Agreements

Leading suppliers are expanding long-term dairy base powder supply agreements across multiple domestic sourcing regions to reduce reliance on single-source spot purchasing, converting a variable input cost exposure into a more predictable, diversified material base across their production network. This diversification strategy has proven valuable during periods of dairy shortage that squeeze non-diversified competitors hardest each cycle.

Redesigning Formulations Around Available Ingredient Grades

Suppliers are redesigning manufacturing processes and formulations around more readily available ingredient grades to reduce exposure to single-specification shortages that have periodically delayed production schedules across the wider industry each year. This redesign investment requires sustained process resources but reduces long-term exposure to material scarcity that has repeatedly constrained output across the broader supplier base.

Vertically Integrating Dairy Sourcing Capacity

Larger suppliers are acquiring or expanding their own dedicated dairy base powder sourcing capacity to reduce dependence on open-market material purchasing, trading some flexibility for supply certainty and cost predictability across their production network overall. Smaller new-entrant brands without comparable sourcing scale remain more exposed to material cost volatility during periods of tight domestic market availability.

Portfolio Architecture for Margin Defence

US infant formula suppliers operate across three margin tiers built around transparency sophistication and application depth rather than simple unit volume. Commodity-adjacent standard and store-brand formats sit at the volume base, certified organic and A2 protein systems occupy the middle at meaningfully firmer margins, and next-generation HMO-enriched and specialty formats sit at the top, commanding premium pricing that few store-brand competitors can currently match. Most established suppliers participate across all three tiers, weighting investment toward whichever tier retail demand currently favours most.
The volume-premium tension plays out most visibly in how suppliers allocate scarce manufacturing and R&D resources: every production cycle dedicated to a standard format is a cycle not available for higher-margin HMO development, so suppliers increasingly prioritise premium allocation even when it means directing WIC-contract customers toward longer lead times overall.

High-value margin pools concentrate in HMO-enriched and organic formats, both of which command pricing closer to specialty nutrition ingredient economics than to standard commodity formula pricing. Suppliers that can move a retailer from conventional formula supply into an HMO-enriched relationship capture meaningfully more of total account value across the life of the contract.

Volume / Commodity-Adjacent Tier

Standard and store-brand formats sold at scale into WIC contracts and mainstream retail applications, priced close to established commodity dairy benchmarks with limited technical differentiation between qualified suppliers competing mainly on price and delivery reliability.
Gross Margin: 12-18%

Premium / Certified Tier

Certified organic and A2 protein systems requiring extensive documentation and quality validation investment, commanding a defensible premium given the technical investment behind each qualified system. Buyers weigh compliance documentation and digestibility performance heavily.
Gross Margin: 19-27%

Sustainability / Regulatory / Next-Generation Tier

Next-generation HMO-enriched and specialty formats carrying the deepest research and regulatory investment, sold primarily into retailers' highest-visibility premium shelf placements. Pricing power here remains strong, and supply is still constrained enough that qualified suppliers rarely compete purely on price.
Gross Margin: 28-38%
us-infant-formula-market-trends-portfolio-architecture-1787457114583

High-value Sub-segments and Strategic Watch-out

HMO-Enriched and A2 Protein Formats

HMO-enriched and A2 protein formats carry the category's highest margins and fastest growth, driven by parents seeking documented composition and digestibility outcomes beyond what standard formats can provide alone. Early movers here are capturing outsized specification share ahead of slower-moving legacy competitors, and that lead looks increasingly durable.
Gross Margin: 28-38%

Ingredient Substantiation and Certification Contracts

Ingredient substantiation and composition certification support service contracts carry strong margins and steady growth, anchored in multi-year relationships that renew predictably as retailers expand certified sourcing specification across additional shelf programmes. Suppliers with proven certification platforms renew these agreements almost automatically over time each year.
Gross Margin: 19-27%

Standard and Store-Brand Formats

Standard and store-brand formats remain the category's volume anchor, growing steadily with overall birth-rate-linked demand but carrying commodity-level margins that make it a scale rather than profit driver for most suppliers. Suppliers defend this tier mainly to preserve WIC contract reach and long-term retailer relationships nationwide.
Gross Margin: 12-18%

New-Entrant Digital-Native Brands

Digitally native new-entrant brands focused narrowly on premium subscription-based distribution represent a long-term competitive threat to established suppliers' retail pricing power, particularly as parents increasingly favour direct-to-consumer certified brands over legacy retail-only formula for premium subscription programmes nationwide, especially across transparency-focused categories where legacy brand loyalty offers little protection.
Gross Margin: 10-16%

From Commodity Can to Transparency Asset

Infant formula purchasing is shifting from a fragmented commodity decision toward a transparency partnership that resembles an ongoing brand relationship more than a series of one-time transactions. Suppliers that embed ingredient transparency documentation and substantiation support into standard retail agreements lock in renewal shelf space, while retailer category teams treat certified HMO-enriched formats as the starting assumption for new shelf planning rather than an alternative considered only after competitive pressure forces the decision.
Adoption depth varies sharply by end-use vertical. Premium subscription-based and direct-to-consumer brands show the deepest reliance on HMO-enriched and certified organic formats, since claim consequences are most acute in categories facing direct parent trust scrutiny. Standard WIC-contracted applications show steadier, less certification-driven demand, since specification decisions there track cost and program eligibility more than transparency documentation requirements specifically.

A generational shift among new parents is reinforcing the trend. Younger parents trained during the recent transparency and ingredient-scrutiny wave treat certified-first specification as standard practice, while older caregivers accustomed to brand-loyalty purchasing are adapting more slowly, defaulting to familiar standard sourcing until forced by a supply disruption or pediatrician recommendation change. Trust rebuilds slowly but decisively once broken.
us-infant-formula-market-trends-end-use-penetration-index-1787457115074

Where MMA Sees the Real Opportunity

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / INGREDIENT TRANSPARENCY INVESTMENT

Build transparency capability ahead of substantiation demand

Suppliers that build comprehensive ingredient transparency documentation and composition testing capability now are positioned to capture new retailer relationships meaningfully faster than suppliers dependent entirely on unsubstantiated generic formulations competing for the same transparency-driven purchasing decisions across every major retail channel. This positioning matters more than competing purely on unit pricing, since transparency capability, not raw manufacturing scale alone, increasingly determines which supplier wins large retailer contracts. MMA recommends prioritising transparency investment over incremental conventional capacity expansion in the current three-year window.
02 / DAIRY SUPPLY DEVELOPMENT

Build dairy supply capability ahead of demand

Suppliers that build integrated long-term dairy supply agreement capability ahead of confirmed demand capture a disproportionate share of the cost stability that follows every dairy price cycle, since retailers rarely switch suppliers once a stable-cost relationship is validated against a specific formulation. Suppliers still relying on open-market dairy purchasing are ceding margin protection to competitors already investing in supply capability. MMA views dairy supply investment as the single highest-return near-term opportunity available within the category over the next three fiscal years.
03 / INGREDIENT SUBSTANTIATION SERVICES

Bundle certification support into every retail sale

Suppliers that bundle ingredient substantiation and composition documentation support into every retail sale capture deeper account penetration and higher switching costs than product-only competitors, providing a durable differentiation advantage that pure product suppliers cannot easily replicate. Suppliers concentrated purely in product sales face meaningfully more price-competitive dynamics than certification-focused competitors carrying broader account value and considerably stronger renewal terms overall. MMA recommends building or acquiring certification capability as a durable differentiation strategy for suppliers currently overexposed to product-only competition today.
04 / SHARED MANUFACTURING ACCESS

Build shared manufacturing capacity access now

New-entrant brands managing budget-constrained expansion timelines increasingly require guaranteed contract manufacturing capacity access, and suppliers with established shared access capability face a genuinely lower-risk competitive position than competitors relying purely on fully independent manufacturing investment requirements. Competitors that moved early on shared access investment are capturing differentiated, multi-year retail contract advantages years ahead of brands still exposed to independent-investment adoption risk today. MMA recommends prioritising shared access investment as a durable, capital-efficient differentiation strategy readily available to brands of every size and scale.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
US Infant Formula Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on US Infant Formula Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-sized regional US grocery retail chain operating multiple store banners across a single metropolitan market, facing rising customer demand for certified transparent private-label infant formula without a coordinated supplier transition strategy. The chain reported annual private-label nutrition category revenue in the low tens of millions of dollars (client-reported, unverified by MMA) and had relied on a single legacy store-brand contract manufacturer without a systematic transparency programme.
STRATEGIC CHALLENGE
The chain faced growing customer pressure to convert its private-label formula line to certified transparent sourcing across multiple product formats simultaneously, but limited category budget meant a phased supplier transition was unavoidable, requiring a defensible framework for prioritising which formats to convert first. Management needed a strategy balancing customer transparency expectations, conversion cost, and supply continuity across a multi-year sourcing programme.
MMA APPROACH
MMA's engagement team benchmarked available contract manufacturers against the chain's category-specific sales volumes and customer feedback data, interviewed suppliers to assess transparency certification track record, and modelled conversion cost and supply continuity impact across three prioritisation scenarios. The team recommended a phased conversion that prioritised the chain's highest-volume standard format first while securing supplier certification commitments ahead of the next planogram reset.
KEY FINDINGS
  1. The chain's standard powdered format accounted for a disproportionate share of total private-label category revenue (client-reported, unverified by MMA), making it the clear priority for transparency conversion investment.
  2. Suppliers offering integrated substantiation support delivered meaningfully faster conversion timelines than suppliers expecting the chain to manage transparency documentation independently during the transition process.
  3. Certified transparent formula costs for the chain's highest-volume format exceeded initial budgeting assumptions the planning team had used by a wider margin than anticipated.
  4. Early supplier engagement during the conversion process reduced total sourcing modernization cost compared with the chain's historical practice of finalising specifications before requesting supplier quotes.
CLIENT PROFILE
The client is a mid-sized regional US grocery retail chain operating multiple store banners across a single metropolitan market, facing rising customer demand for certified transparent private-label infant formula without a coordinated supplier transition strategy. The chain reported annual private-label nutrition category revenue in the low tens of millions of dollars (client-reported, unverified by MMA) and had relied on a single legacy store-brand contract manufacturer without a systematic transparency programme.
STRATEGIC CHALLENGE
The chain faced growing customer pressure to convert its private-label formula line to certified transparent sourcing across multiple product formats simultaneously, but limited category budget meant a phased supplier transition was unavoidable, requiring a defensible framework for prioritising which formats to convert first. Management needed a strategy balancing customer transparency expectations, conversion cost, and supply continuity across a multi-year sourcing programme.
MMA APPROACH
MMA's engagement team benchmarked available contract manufacturers against the chain's category-specific sales volumes and customer feedback data, interviewed suppliers to assess transparency certification track record, and modelled conversion cost and supply continuity impact across three prioritisation scenarios. The team recommended a phased conversion that prioritised the chain's highest-volume standard format first while securing supplier certification commitments ahead of the next planogram reset.
KEY FINDINGS
  1. The chain's standard powdered format accounted for a disproportionate share of total private-label category revenue (client-reported, unverified by MMA), making it the clear priority for transparency conversion investment.
  2. Suppliers offering integrated substantiation support delivered meaningfully faster conversion timelines than suppliers expecting the chain to manage transparency documentation independently during the transition process.
  3. Certified transparent formula costs for the chain's highest-volume format exceeded initial budgeting assumptions the planning team had used by a wider margin than anticipated.
  4. Early supplier engagement during the conversion process reduced total sourcing modernization cost compared with the chain's historical practice of finalising specifications before requesting supplier quotes.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 6): Convert the standard powdered format to certified transparent sourcing immediately, securing early customer trust recognition. Phase 2: Phase 2 (Months 7 to 15): Secure certification commitments and convert the remaining formats, sequencing by volume and budget availability. Phase 3: Phase 3 (Months 16 to 20): Complete chain-wide conversion and consolidate all supplier relationships across the full private-label nutrition portfolio.
OUTCOME
Following the engagement, the client reported a meaningful reduction in customer transparency inquiries and improved competitive shelf positioning across its converted formats, avoiding the reputational risk it had initially feared (client-reported, unverified by MMA). The phased transition reduced total conversion cost relative to the chain's budget.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the US Infant Formula Market?

The US market reached approximately $10.3 billion in 2026. Demand is concentrated in standard cow's milk and WIC-contracted formats, with HMO-enriched formula emerging as the fastest-growing category.

How large will the US Infant Formula Market be by 2036?

MMA projects the market will reach approximately $19.9 billion by 2036. That represents roughly a 1.93 times increase over 2026 revenue across the ten-year forecast period.

What is the CAGR for the US Infant Formula Market 2026 to 2036?

The base case compound annual growth rate is 6.8 percent. Bull and bear scenarios range from roughly 5.6 percent to 8.0 percent depending on HMO capacity expansion and organic substantiation pace.

Which segment is growing fastest?

HMO-enriched and specialty formula is growing fastest, at roughly 1.71 times the overall market rate. Rising parent transparency and breast-milk-similarity demand are the primary drivers behind that outperformance.

Who are the major companies in the US Infant Formula Market?

Five suppliers, led by Abbott Laboratories, Reckitt Benckiser Group plc, and Nestle S.A., lead the market. Together the top five hold roughly 68 percent of US infant formula revenue.

Which country is growing fastest?

This report covers the United States exclusively, so the US itself is the reference market at the overall base rate. Its infant formula demand is expanding at roughly 6.8 percent annually.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Formula Type

  • Standard Cow's Milk-Based Formula
  • Organic Infant Formula
  • HMO-Enriched and Specialty Formula
  • Hypoallergenic and Hydrolyzed Formula
  • Toddler and Follow-On Formula
  • Goat Milk and A2 Protein Formula

By End-Use Industry

  • Retail Grocery and Mass Merchandise Channels
  • State WIC Program Contracts
  • Direct-to-Consumer Subscription Brands
  • Hospital and Clinical Nutrition Channels

By Commercial Dimension

  • Branded National Manufacturer Sales
  • Private-Label Store-Brand Manufacturing
  • Ingredient Substantiation and Certification Services
  • Direct-to-Consumer E-Commerce Sales

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
The US infant formula market covers powdered, liquid concentrate, and ready-to-feed infant and toddler formula products manufactured and sold within the United States, spanning standard cow's milk-based, organic, HMO-enriched, hypoallergenic and hydrolyzed, and goat milk or A2 protein formats. It excludes breast milk fortifiers sold exclusively through hospital and clinical channels, adult nutritional formula, and infant formula manufactured domestically for export outside the United States.
Quantitative Units
USD billions (current prices); annual metric ton volume where applicable
Segmentation Dimensions
By Formula Type; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
United States (primary scope); Ireland, Netherlands, Germany, Switzerland, United Kingdom, China, Japan, South Korea, Taiwan, New Zealand, Australia, India, Mexico, Brazil, Colombia, Saudi Arabia, UAE, South Africa, Poland, Czech Republic, Hungary (ingredient trade and supply chain context only)
Key Companies Profiled
Abbott Laboratories, Reckitt Benckiser Group plc, Nestle S.A., Danone S.A., Perrigo Company plc, ByHeart Inc, Bobbie Baby Inc, Bellamy's Organic, Else Nutrition Holdings Inc, Kendal Nutricare Limited, HiPP GmbH and Co Vertrieb KG, Holle baby food AG, Gerber Products Company, Walmart Inc, The Kroger Co, Target Corporation, Nature's One Inc, Arla Foods amba, FrieslandCampina N.V., Synlait Milk Limited
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-AGR-329
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full US Infant Formula Market Report (2026 to 2036).

The full report delivers a complete quantitative and qualitative assessment of the US infant formula market across all major retail and distribution channels. It includes detailed state-level sizing for the fifteen largest WIC contract and retail markets, full profiles of all twenty companies named in the competitive landscape, and a complete database of corporate developments tracked over the trailing eighteen months. Analysts provide segment-by-segment margin benchmarking derived from primary interviews with forty-seven infant nutrition and regulatory affairs experts, alongside an ingredient transparency claim substantiation regulatory tracker covering FDA and state-level requirements. Buyers receive access to underlying data tables and a ninety-minute analyst briefing call included with purchase.
State-level sizing for fifteen major WIC contract and retail markets
Full profiles of all twenty companies profiled
Ingredient transparency claim substantiation regulatory tracker
Segment-level margin benchmarking from primary expert interviews
Eighteen-month corporate development and manufacturing capacity database
Ninety-minute analyst briefing call included with purchase

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts